Here are the 10-K annual reports from Dermata Therapeutics, Inc. Warrant (DRMAW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow DRMAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DRMAW filings page.
Dermata Therapeutics, Inc. files its annual report describing a major strategic shift from prescription dermatology to over-the-counter and cosmetic skincare under its new Tome brand. After achieving statistically significant Phase 3 results in 2025 for its acne candidate XYNGARI, the company chose not to pursue the traditional prescription path and instead focus on faster-to-market consumer products.
Dermata plans to commercialize once-weekly Tome Foundational Treatment and a Clearing Treatment acne system built around its proprietary Bioneedle technology, derived from the freshwater sponge Spongilla lacustris. The products are intended to offer skin renewal and acne control with simplified routines and natural ingredients.
The company outlines a dual go-to-market strategy combining direct-to-consumer e-commerce with a professional B2B channel, including a Tome certification program for aestheticians and dermatology practices. It also highlights potential future applications of Bioneedle for broader skin conditions and a paused collaboration using the platform for topical delivery of botulinum toxin.